Mary Butler explores a recent randomised controlled trial of probiotic formulations for patients with bipolar disorder or schizophrenia spectrum disorder.
[read the full story...]Probiotics for bipolar disorder and schizophrenia
No Responses »
Smoking and depression: a burning issue for the elf care community
Gemma Taylor discusses new research on the effects of smoking cessation treatment options for people with past or current major depressive disorder.
[read the full story...]Time to ACT for insomnia? New trial finds possible alternative to CBTi
Nicholas Donnelly considers a recent Brazilian randomised controlled trial of Acceptance and Commitment Therapy versus Cognitive Behavioural Therapy for insomnia.
[read the full story...]Quetiapine may pip lithium to the post for augmentation in ‘treatment resistant depression’: results from the LQD study
Kirsten Lawson and Douglas Badenoch review the new randomised controlled trial by Cleare et al, published today in The Lancet Psychiatry, directly comparing the clinical and cost effectiveness of lithium and quetiapine as augmentation treatments for patients with ‘treatment resistant depression’.
[read the full story...]Home-based brain stimulation (tDCS) for depression: ready for widespread use?
Julian Mutz discusses the results of a new 10-week RCT assessing home-based brain stimulation for depression, which suggests that tDCS may be a safe, acceptable and efficacious treatment for moderate depression.
[read the full story...]Will this ADHD medication help my patient? Bridging the gap between efficacy and effectiveness
Shuichi Suetani blogs a new study published today in The Lancet Psychiatry, which suggests that those patients who might benefit most from evidence-based guidance are the least represented in clinical trials about ADHD medication. Is it time to reconsider the value we place on RCTs when they do not include the vast majority of people who need help?
[read the full story...]Omega-3 supplements for the prevention of psychosis: another trial shows no benefit, so is it time to move on?
David Mongan reports on a recent trial of omega-3 supplementation for the prevention of psychosis in people at ultra-high risk, which finds no evidence of a positive effect. He reflects on these findings and considers what’s next for the field.
[read the full story...]KarXT: an innovative and promising treatment for schizophrenia
Nicola Rizzo Pesci and Andrea Cipriani summarise findings from the EMERGENT-2 trial spotlighting a promising new drug treatment for schizophrenia.
[read the full story...]ACT now for MND: acceptance and commitment therapy can improve quality of life for people with motor neuron disease
Dona Matthews summarises a recent trial which suggests that Acceptance and Commitment Therapy can maintain or improve quality of life for people with early stage motor neuron disease.
[read the full story...]Can self help apps PROMOTE wellbeing or PREVENT illness in young adults?
Kirsten Lawson summarises the ECoWeB PROMOTE and PREVENT trials in relation to self-helps apps for promoting wellbeing and preventing mental ill health among young adults.
[read the full story...]